To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

NCT00100074 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

8

Enrollment

NIH

Sponsor class

Conditions

Amphetamine-Related Disorders

Interventions

DRUG: Lobeline

Sponsor

National Institute on Drug Abuse (NIDA)